CLLS - Cellectis S.A.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
20.09
+0.21 (+1.06%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close19.88
Open19.71
Bid20.10 x 1000
Ask20.50 x 900
Day's Range19.67 - 20.15
52 Week Range15.34 - 31.57
Volume102,964
Avg. Volume135,829
Market Cap835.206M
Beta (3Y Monthly)1.60
PE Ratio (TTM)N/A
EPS (TTM)-1.93
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est41.90
Trade prices are not sourced from all markets
  • Business Wire2 days ago

    Cellectis Announces Oral and Poster Presentations of Allogeneic CAR T-Cell Programs at the 2019 ASGCT Annual Meeting

    - Oral presentation to include preclinical UCARTCS1A data in Multiple Myeloma

  • Benzinga16 days ago

    The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 2) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's ...

  • Business Wire17 days ago

    FDA Clears the IND for UCARTCS1, the First Allogeneic CAR-T to Treat Multiple Myeloma Patients

    Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), announced today that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational New Drug (IND) application to initiate a Phase 1 clinical trial for UCARTCS1, in patients with multiple myeloma (MM). The IND for UCARTCS1 was filed on December 28, 2018 and approved by the FDA within a month, on January 25, 2019. Cellectis is the sponsor of the UCARTCS1 clinical study (MUNDI-01) and successfully ensured the manufacturing and release of UCARTCS1 GMP batches, as well as an IRB approval.

  • Business Wirelast month

    Cellectis Reports 4th Quarter and Full Year 2018 Financial Results

    NEW YORK-- -- UCART123 in Phase 1 dose escalation clinical trial ongoing for AML; UCART22 received FDA and IRB approvals for Phase 1 dose escalation clinical trial in B-ALL patients; UCART19 ASH abstract by partners Servier and Allogene showed continued progress of first clinical allogeneic CAR T-cell program for ALL adult and pediatric patients; Cellectis, through its new subsidiary Cellectis Biologics, ...

  • Business Wirelast month

    Cellectis Enters Lease Agreement to Build Manufacturing Facility, Advancing Towards Commercialization of its UCART Portfolio

    Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced that it has entered into a lease agreement to build an 82,000 square foot commercial-scale manufacturing facility named IMPACT (Innovative Manufacturing Plant for Allogeneic Cellular Therapies) in Raleigh, North Carolina, for clinical and commercial production of Cellectis’ leading allogeneic UCART products. In addition, Cellectis started building a 14,000 square foot manufacturing facility in Paris, France named SMART (Starting Material Realization for CAR-T products) to produce Cellectis’ critical starting material supply for UCART clinical studies and commercial products.

  • 5 Top Gene-Editing Stocks for 2019
    Motley Foollast month

    5 Top Gene-Editing Stocks for 2019

    The future of treating disease might be gene editing, and these five stocks have the most promising technologies.

  • Business Wire2 months ago

    Cellectis Publishes Novel Methods to Improve the Safety of CAR T-Cell Therapy and Prevent CRS in the Journal of Biological Chemistry

    Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-Cells prevents monocyte-dependent release of key cytokine release syndrome mediators

  • GlobeNewswire2 months ago

    Consolidated Research: 2019 Summary Expectations for Oceaneering International, Southwest Gas, WellCare Health Plans, Barnes & Noble, Cellectis S.A, and Payment Data — Fundamental Analysis, Key Performance Indications

    NEW YORK, Feb. 07, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Business Wire4 months ago

    Cellectis Appoints William Monteith as Senior Vice President U.S. Manufacturing

    Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), today announced the appointment of William (Bill) Monteith to the role of Senior Vice President U.S. Manufacturing. This appointment follows Cellectis’ plan to establish commercial manufacturing capabilities in the U.S., which will be Bill Monteith’s responsibility, notably through the deployment of a proprietary state-of-the-art gene-edited cell manufacturing plant for clinical and commercial supplies of our current immuno-oncology UCART product candidates. Bill Monteith joins Cellectis from Hitachi Chemical Advanced Therapeutics Solutions, where he was the Chief Operating Officer and Site General Manager for three manufacturing facilities.

  • Business Wire5 months ago

    Cellectis Reports Financial Results for 3rd Quarter and First Nine Months 2018

    NEW YORK-- -- UCART123 in Phase 1 clinical trial for AML and BPDCN patients; UCART22 Phase 1 study protocol approved by FDA for B-ALL patients; UCART19 ASH abstract by partner Servier shows continued progress of first clinical allogeneic CAR T-cell program for ALL patients; UCARTCS1 clinical trial expected to start in 2019 for Multiple Myeloma patients; Cash 1 position of $476M as of September 30, ...

  • Business Wire7 months ago

    CAR-T Pioneer Dr. Stephan A. Grupp to Join Cellectis Clinical Advisory Board

    Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), today announced that Stephan A. Grupp, MD, Ph.D., a leading pediatric oncologist at Children's Hospital of Philadelphia and Chief of the Section of Cellular Therapy and Transplant at the Children's Hospital of Philadelphia (CHOP) joined the Company’s Clinical Advisory Board (CAB). Dr. Grupp is a world-renowned pediatric oncologist and cancer researcher who initiated the first pediatric CAR T-cell trial for acute lymphoblastic leukemia at CHOP in 2012.

  • Business Wire7 months ago

    Calyxt Appoints CEO, Jim Blome, Former President & CEO of Bayer CropScience LP

    Calyxt, Inc. (CLXT) and Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) announced today the appointment of James A. Blome, former President and CEO of Bayer CropScience LP (North America), as Chief Executive Officer of Calyxt, effective October 1, 2018. Jim Blome will work closely with Calyxt’s Board of Directors to foster the development of the Company’s consumer-focused products, including the upcoming commercial launch of Calyxt’s first product, high-oleic soybean oil. Jim Blome is a high-impact, global leader with over 25 years of leadership experience in the agriculture industry, building teams and strategies with consumer-focused cultures to better meet consumer needs and maximize market share growth.

  • Business Wire9 months ago

    Cellectis Appoints Stefan Scherer M.D., Ph.D., as Senior Vice President Clinical Development and Deputy Chief Medical Officer

    Cellectis (ALCLS.PA) (CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today the appointment of Dr. Stefan Scherer, M.D., Ph.D., to the role of Senior Vice President Clinical Development and Deputy Chief Medical Officer. Dr. Scherer joins Cellectis from Novartis Pharmaceuticals Corporation, where he was the Head of Early Development, Strategy and Innovation for U.S. Oncology.

  • Business Wire9 months ago

    Cellectis Reports Financial Results for 2nd Quarter and First Six Months 2018

    NEW YORK-- -- FDA approves UCART123 protocol amendment to accelerate clinical development in AML patients FDA approves IND for UCART22 in B-ALL patients, which is the 3 rd allogeneic gene-edited CAR T-cell product candidate approved for clinical trials in the United States Allogene and Servier alliances to accelerate commercialization of allogeneic CAR T-Cell therapies $191M follow-on offering by Cellectis ...

  • Business Wire10 months ago

    Cellectis Publishes Novel Methods to Improve the Clinical Use of Chimeric Antigen Receptor T-Cell Therapy in Scientific Reports

    Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), today announced the publication of a study in Scientific Reports, a Nature Publishing Group journal, describing the development of the CubiCAR, an all-in-one Chimeric Antigen Receptor (CAR) architecture with an embedded multi-functional tag for purification, detection and elimination of CAR T-cells. This added versatility has the potential to streamline the manufacturing of CAR T-cells to allow their tracking and efficiently eliminate CAR T-cells in clinical settings. To identify an optimal CAR architecture, we selected 15 different CAR constructs and evaluated their ability to enable T-cell depletion and promote tumor eradication,” said Julien Valton, Ph.D., Innovation Team Leader of Cellectis.

  • Should Cellectis SA.’s (NASDAQ:CLLS) Recent Earnings Decline Worry You?
    Simply Wall St.10 months ago

    Should Cellectis SA.’s (NASDAQ:CLLS) Recent Earnings Decline Worry You?

    Assessing Cellectis SA.’s (NASDAQ:CLLS) past track record of performance is a useful exercise for investors. It allows us to understand whether the company has met or exceed expectations, which isRead More...

  • Business Wire10 months ago

    FDA Grants Cellectis IND Approval for UCART22 in B-ALL

    Cellectis (ALCLS.PA) (CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational New Drug (IND) application to initiate a Phase 1 clinical trial for UCART22, Cellectis’ second wholly controlled TALEN® gene-edited product candidate, for the treatment of B-cell acute lymphoblastic leukemia (B-ALL) in adult patients. UCART22 is the 3rd allogeneic, off-the-shelf, gene-edited CAR T-cell product candidate approved by the FDA for clinical trials in the U.S., following UCART19 (exclusively licensed to Servier and under joint development agreement between Servier and Allogene), and Cellectis’ UCART123.

  • Business Wire11 months ago

    INSERTING and REPLACING: Approval of UCART123 Amendment in AML to Accelerate Clinical Development

    Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today the approval of an amendment to the protocol for the Phase 1 clinical trial of Cellectis’ UCART123 product candidate in patients with acute myeloid leukemia (AML). Dose level 1 to be administered increases from 6.25x104 to 2.5x105 UCART123 cells per kilogram. Dose level -1 is now at 1.25x105.

  • Business Wire11 months ago

    Cellectis: Approval of UCART123 Amendment in AML to Accelerate Clinical Development

    Cellectis (ALCLS.PA) (CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today the approval of an amendment to the protocol for the Phase 1 clinical trial of Cellectis’ UCART123 product candidate in patients with acute myeloid leukemia (AML). The product’s safety and tolerability profile allowed Cellectis to increase the dose level.